Please note that slides are for review only and not to be repurposed or published.
Keynote
Ethan M Basch, MD, MSc
Improving Patient and Physician Communication: Recap of ASCO 2017 Plenary Presentation on Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment and Discussion of How This Research Can Be Applied to Routine Care
SESSION 1: Management of Non-Small Cell Lung Cancer (NSCLC) with a Targetable Mutation — Part 1
Presentation 1 — Dr Tsao
Molecular testing in clinical practice: CAP, IASLC and AMP Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors
Presentation 2 — Dr Riely
Front-line treatment for patients with EGFR tumor mutations; results of the FLAURA trial and clinical implications
Presentation 3 — Dr Sequist
Treatment for patients with disease progression on a first-line EGFR tyrosine kinase inhibitor (TKI), including osimertinib; role of mutation testing
Presentation 4 — Dr Gubens
Selection of first-line therapy for patients with ALK-rearranged or ROS1- positive NSCLC; implications of the ALEX study
SESSION 2: Management of NSCLC with a Targetable Mutation — Part 2
Presentation 5 — Dr Gandhi
Identification of and treatment for patients with BRAF V600E mutations and MET mutations/amplifications
Presentation 6 — Dr Hanna
Potential clinical benefits and investigational opportunities associated with the identification of HER2 mutations and RET rearrangements
Presentation 7 — Dr Riely
Optimal management of CNS metastases in patients with a targetable mutation
Presentation 8 — Dr Sequist
Effectiveness and role of immunotherapy in patients with tumor driver mutations
SESSION 3: Current and Future Application of Immunotherapy in Lung Cancer — Part 1: NSCLC
Presentation 9 — Dr Gubens
PD-L1, tumor mutation burden and other potential predictors of response to immune checkpoint inhibition in NSCLC
Presentation 10 — Dr Hanna
Emerging research data with and potential clinical role of immune checkpoint inhibitors in the management of locally advanced NSCLC
Presentation 11 — Dr Garon
Integration of anti-PD-1/ PD-L1 antibodies into current treatment algorithms for patients with metastatic NSCLC
Presentation 12 — Dr Socinski
Novel immunotherapeutic approaches, including combination strategies; current role of anti-angiogenics in NSCLC
SESSION 4: Current and Future Application of Immunotherapy in Lung Cancer — Part 2: Small Cell Lung Cancer (SCLC) and Malignant Pleural Mesothelioma (MPM)
Presentation 13 — Dr Garon
Optimal duration of anti- PD-1/PD-L1 therapy for patients experiencing a clinical response; continuation of an immune checkpoint inhibitor upon disease progression
Presentation 14 — Dr Lilenbaum
Does hyperprogression occur in patients receiving an anti-PD-1/ PD-L1 antibody?
Presentation 15 — Dr Gandhi
Current management and ongoing clinical trials in SCLC, including immunotherapy and antibody-drug conjugates
Presentation 16 — Dr Tsao
Emerging role of immune checkpoint inhibitors and other novel strategies in MPM
SESSION 5: Meet the Professors: Palliative Care and Psychiatric Support for Patients with NSCLC
Presentation 1 — Dr Kapo
Palliative care in lung cancer management: New clinical research findings; patterns of care in the community
Presentation 2 — Dr Fann
Update on clinical research on the management of psychiatric/psychologic issues in lung cancer management; case discussions
SESSION 6: Surgery, Radiation Therapy and Other Issues in the Management of NSCLC
Presentation 3 — Dr Loo
Radiation therapy: Challenging clinical scenarios and related management issues
Presentation 4 — Dr Wood
Update on the surgical management of lung cancer
Presentation 5 — Dr Crawford
Optimal management of oligometastatic disease
Presentation 6 — Dr Rizvi
Trials evaluating checkpoint inhibitors and targeted therapy in the adjuvant and neoadjuvant settings
SESSION 7: Practical Clinical Issues in the Treatment of Locally Advanced NSCLC in the Current Era
Presentation 7 — Dr Wood
Indications for surgery in patients with locally advanced disease; role, if any, of neoadjuvant chemotherapy for NSCLC
Presentation 8 — Dr Loo
Incidence and management of toxicities in patients with locally advanced disease receiving chemoradiation therapy
Presentation 9 — Dr Rizvi
Management of toxicities associated with immune checkpoint inhibitors in the locally advanced and metastatic settings
Presentation 10 — Dr Crawford
Immunotherapy in patients with a history of autoimmune disease or paraneoplastic syndromes in the locally advanced and metastatic settings
Download All
Download all slides (ZIP file)
